论文部分内容阅读
目的:观察双歧三联活菌辅助治疗对肝硬化患者肠道菌群、血浆内毒素及肠黏膜屏障功能的影响。方法:70例肝硬化患者随机分为对照组和观察组各35例。对照组患者给予对症支持治疗,观察组在对照组基础上加用双歧三联活菌胶囊治疗。疗程均为4周。比较两组患者治疗前后肠道菌群(肠杆菌、肠球菌、双歧杆菌、乳杆菌、酵母样真菌)、血浆内毒素及降钙素原(PCT)、二胺氧化酶(DAO)等肠黏膜屏障功能指标变化。结果:治疗后,观察组肠杆菌、肠球菌、双歧杆菌、乳杆菌等菌落数均明显高于治疗前及对照组治疗后(P<0.05),而酵母样真菌菌落数明显低于治疗前及对照组治疗后(P<0.05)。两组治疗后血浆内毒素及PCT、DAO等表达水平均较治疗前明显下降(P<0.05),且观察组明显低于对照组(P<0.05)。两组患者治疗期间均未出现严重的药品不良反应。结论:双歧三联活菌辅助治疗可促进肝硬化患者肠道菌群恢复,降低血浆内毒素水平,提高肠道黏膜屏障功能,值得临床推广应用。
Objective: To observe the effects of adjuvant bifidobacterium triple therapy on the intestinal microflora, endotoxin and intestinal mucosal barrier in patients with liver cirrhosis. Methods: Seventy patients with cirrhosis were randomly divided into control group and observation group of 35 cases. Patients in the control group were given symptomatic and supportive treatment. The observation group was treated with bifid triple viable capsule on the basis of the control group. The course of treatment is 4 weeks. The intestinal flora (Enterobacteriaceae, Enterococcus, Bifidobacterium, Lactobacillus, Yeast-like fungi), plasma endotoxin and procalcitonin (PCT) and diamine oxidase (DAO) Mucosal barrier function index changes. Results: After treatment, the number of colonies such as Enterobacter, Enterococcus, Bifidobacterium and Lactobacillus in observation group were significantly higher than those before treatment and control group (P <0.05), while the number of yeast-like colonies was significantly lower than that before treatment And control group after treatment (P <0.05). The levels of plasma endotoxin, PCT and DAO in both groups after treatment were significantly lower than those before treatment (P <0.05), and the observation group was significantly lower than the control group (P <0.05). Two groups of patients during the treatment did not appear serious adverse drug reactions. Conclusion: The adjuvant treatment of Bifidobacterium triple viable bacteria can promote the recovery of intestinal microflora in patients with liver cirrhosis, reduce the plasma endotoxin level and improve the intestinal mucosal barrier function, which deserves clinical application.